Clinical trial
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or…
NCT00498927 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00498927 |
|---|---|
| Title | Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma |
| Official title | A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Weill Medical College of Cornell University Schering-Plough Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Genetic, Other |
| Interventions | temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunoenzyme technique |
| Enrollment | 47 |
| Start date | Jun 1, 2007 |
| Primary completion | Dec 1, 2013 |
| Completion | Dec 1, 2013 |
| First posted | Jul 11, 2007 |
| Last update posted | Feb 29, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: